[HTML][HTML] Meta-analysis assessing the effectiveness of SGLT2i+ GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in …
L Du, J Qin, D Wang, Y Zhao, N Xu, C Wu… - Frontiers in …, 2022 - frontiersin.org
Relevant meta-analyses have confirmed the cardiovascular and renal benefits of sodium-
glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists …
glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists …
[HTML][HTML] Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in …
XY Duan, SY Liu, DG Yin - Medicine, 2021 - journals.lww.com
Background: Sodium glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide
1 receptor agonists (GLP-1 RAs) have been demonstrated to be able to improve the …
1 receptor agonists (GLP-1 RAs) have been demonstrated to be able to improve the …
Combination therapy with SGLT2 inhibitor and GLP-1 receptor agonist in type 2 diabetes
AJ Scheen - Revue Medicale Suisse, 2019 - europepmc.org
Some sodium-glucose cotransporter type 2 inhibitors (SGLT2is) and glucagon-like peptide-1
receptor agonists (GLP-1RAs) have proven their ability to reduce major cardiovascular …
receptor agonists (GLP-1RAs) have proven their ability to reduce major cardiovascular …
Effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors and combined SGLT1/2 inhibitors on cardiovascular, metabolic, renal, and safety outcomes in patients …
YN Teo, AZH Ting, YH Teo, EY Chong, JTA Tan… - American Journal of …, 2022 - Springer
Introduction Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of anti-
hyperglycemic drugs that has been steadily increasing in popularity due to its cardiovascular …
hyperglycemic drugs that has been steadily increasing in popularity due to its cardiovascular …
[HTML][HTML] Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status
L Du, Z Li, P Lan, H Huang, W Cheng - Frontiers in Cardiovascular …, 2022 - frontiersin.org
Methods This meta-analysis was performed on the basis of the statement of Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)(2). We searched …
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)(2). We searched …
Combinaison<< inhibiteur des SGLT2-agoniste des recepteurs du GLP-1>> pour traiter le diabete de type 2.
A Scheen - Revue Médicale Suisse, 2019 - orbi.uliege.be
Some sodium-glucose cotransporter type 2 inhibitors (SGLT2is) and glucagon-like peptide-1
receptor agonists (GLP-1RAs) have proven their ability to reduce major cardiovascular …
receptor agonists (GLP-1RAs) have proven their ability to reduce major cardiovascular …
Cardiovascular efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: a systematic review and network …
Aims To compare the cardiovascular efficacy and safety of sodium‐glucose co‐transporter‐2
(SGLT 2) inhibitors and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA s) in adults …
(SGLT 2) inhibitors and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA s) in adults …
[HTML][HTML] The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis
MU Ali, GBJ Mancini, D Fitzpatrick-Lewis… - Cardiovascular …, 2024 - Springer
Abstract Background The 2022 Canadian Cardiovascular Society (CCS) cardiorenal
guideline provided clinical recommendations on sodium-glucose co-transport 2 inhibitors …
guideline provided clinical recommendations on sodium-glucose co-transport 2 inhibitors …
[HTML][HTML] Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus …
Background Recent large clinical trials have demonstrated cardiovascular benefits of similar
overall magnitude for sodium–glucose cotransporter-2 inhibitor (SGLT-2i) and glucagon-like …
overall magnitude for sodium–glucose cotransporter-2 inhibitor (SGLT-2i) and glucagon-like …
The effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists on cardiorenal outcomes: systematic review and meta …
MU Ali, GBJ Mancini, D Fitzpatrick-Lewis… - Canadian Journal of …, 2022 - Elsevier
Background Evidence for the cardiorenal risk reduction properties of antihyperglycemic
medications originally prescribed for type 2 diabetes, sodium-glucose cotransporter 2 …
medications originally prescribed for type 2 diabetes, sodium-glucose cotransporter 2 …
相关搜索
- meta analysis sodium glucose
- meta analysis receptor agonists
- meta analysis cardiorenal outcomes
- meta analysis combination therapy
- diabetic patients combination therapy
- meta analysis diabetic patients
- t2d patients glp 1ras
- sglt2 inhibitor combination therapy
- meta analysis sglt2 inhibitors
- meta analysis cardiovascular efficacy
- receptor agonist combination therapy
- cvd status glp 1ras
- meta analysis inhibitors and glucagon
- meta analysis diabetes mellitus